Shares of Sangamo Therapeutics Inc SGMO are higher by 7.6% Monday afternoon.
Photo taken from the ‘Why Is It Moving?’ Details tool inside Benzinga Pro.
Sangamo Therapeutics shares are trading higher after the company presented data from its Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A over the weekend.
Photo taken from the ‘Overview’ Details tool inside Benzinga Pro.
For live updates on SGMO, log in or try Benzinga Pro today.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in